Intensity Therapeutics Q2 2026: Cash Drops to $9.5M, Going Concern Warning Reiterated, Clinical Trials Resume
INTS sits 19% above its 52-week low of $3.51 on light trading volume (0.4× avg).
Summary
Intensity Therapeutics' Q2 2026 filing shows cash declining to $9.5 million with a going concern warning, while key clinical trials resume enrollment. The company raised $1.8 million via its ATM program during the quarter and an additional $1.3 million after quarter-end, but remains in urgent need of capital.
Key Events · Earnings and Guidance · INTS
-
Cash Drops to $9.5M, Going Concern Warning
Cash and cash equivalents fell to $9.5 million as of June 30, 2026, from $10.2 million at March 31, 2026. The company reiterated substantial doubt about its ability to continue as a going concern, citing the need for additional capital.
-
Net Loss of $3.0M in Q2 2026
Net loss was $3.0 million for the quarter, with research and development expenses of $1.8 million and general and administrative expenses of $1.3 million. Operating cash burn was $4.2 million for the first half of 2026.
-
INVINCIBLE-3 Phase 3 Study to Resume Enrollment
The pivotal INVINCIBLE-3 sarcoma study, paused in March 2025 due to funding constraints, is expected to resume patient enrollment in Q3 2026 at a limited number of U.S. sites, with broader activation dependent on securing additional funding.
-
INVINCIBLE-4 Breast Cancer Study Restarts
The INVINCIBLE-4 Phase 2 breast cancer study resumed enrollment in Q2 2026 after a protocol amendment to reduce dosing. The company targets completing enrollment by the end of 2027.
Analysis · INTS · Life Sciences
Intensity Therapeutics' Q2 2026 filing reveals a cash position of $9.5 million, down from $10.2 million at the end of Q1, and reiterates substantial doubt about its ability to continue as a going concern. The company needs additional capital to fund operations and clinical trials. On the operational front, the INVINCIBLE-3 Phase 3 sarcoma study is preparing to resume enrollment in Q3 2026 after a pause, and the INVINCIBLE-4 breast cancer study has restarted enrollment following a protocol amendment. The company continues to rely on its ATM program, raising $1.8 million during the quarter and an additional $1.3 million after quarter-end, but these amounts are modest relative to its burn rate. The CEO took 37,749 shares in lieu of a cash bonus, conserving cash but signaling tight liquidity. The combination of a dwindling cash balance, a going concern warning, and the need for significant funding to advance clinical programs makes this a critical update for investors.
At the time of this filing, INTS was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $3.51 to $43.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.